ImmunityBio, Inc. (IBRX) Down 10.9% — Is It Time to Surrender the Shares?
Key Points
ImmunityBio, Inc. (IBRX) retreated sharply today, falling 10.87% to $10.30 after closing the prior session at $11.55. The stock shed $1.25 in a single day, placing it under clear near-term pressure even as it holds well above the lower end of its 52-week range. The decline also unwound a portion of the recent momentum that had carried shares toward fresh highs, leaving the price action looking more fragile and vulnerable to further selling.
Trading was notably heavy, with approximately 42.8 million shares changing hands compared to a 90-day average of roughly 24.8 million. That surge in volume underscores the conviction behind the move and points to more deliberate repositioning than a routine session would suggest. Even after the pullback, IBRX remains within striking distance of its 52-week high of $12.28, set on 02/24/2026—now roughly 16% below that peak—close enough to highlight just how quickly the stock has surrendered its recent gains.
A double-digit single-session decline is a meaningful sign of weakness, even when compared to other Health Care strugglers like Zoetis (ZTS), BioNTech SE (BNTX), and Natera (NTRA), which tend to trade choppily but rarely move this far in a single session. For investors watching the tape, the message is clear: IBRX is facing genuine headwinds, and the latest move has tilted the near-term trend back toward a defensive posture.
Why ImmunityBio, Inc. Price is Moving Lower
ImmunityBio is encountering renewed selling pressure as traders reassess a sharp, news-driven rally tied to ANKTIVA's EU conditional marketing authorization and optimistic messaging around a broader expansion roadmap. With the initial wave of enthusiasm fading, the market's attention is turning to what lies ahead: execution risk around EU commercialization through the company's Irish subsidiary, the pace at which approvals and partnerships translate into consistent revenue, and the ongoing requirements that accompany a "conditional" authorization. Adding to the uncertainty, Q4 2025 results are due on Mar. 2, and pre-earnings positioning can amplify downside moves—particularly when expectations have been elevated by bullish sentiment and a $11.80 consensus price target that leaves limited room for disappointment.
Underlying fundamentals are also creating headwinds beneath the headline catalysts. While quarterly revenue climbed to $31.78 million from $26.42 million—a 20.3% quarter-over-quarter increase—profitability remains a serious concern. A deeply negative profit margin of -422.28% and an EPS of -$0.42 highlight the company's persistent cash-burn risk. From a technical standpoint, the stock recently pushed above the upper Bollinger Band, a setup that frequently precedes a pullback as momentum exhausts itself. Insider selling has added another layer of uncertainty for investors already on edge. The combination of stretched momentum and weak profitability continues to keep sellers in control.
What is the ImmunityBio, Inc. Rating - Should I Sell?
Weiss Ratings assigns IBRX a D rating, with a current recommendation of Sell. The stock was upgraded on 1/15/2026, but its overall risk/reward profile still places it in underperformer territory relative to stocks with comparable risk levels. The upgrade is best understood as a modest incremental improvement rather than any kind of fundamental clearance—the bar for a genuine turnaround remains high.
IBRX's fundamentals remain uneven. The Good Growth Index is the clearest bright spot, supported by exceptionally rapid top-line expansion with revenue growth of 425.07%. That growth, however, has yet to translate into shareholder-friendly economics. A profit margin of -422.28% reflects heavy and ongoing losses, while a forward P/E of -27.47 makes clear that profitability remains a distant goal. Within Weiss Ratings' framework, fast revenue growth alone is insufficient to offset deteriorating earnings power and meaningful execution risk.
Operating performance is a persistent drag on the overall picture. The Very Weak Efficiency Index points to poor returns on capital and little evidence that investment is being converted into lasting value. The Weak Total Return Index indicates that past stock performance has not adequately compensated investors for the risks assumed, while the Weak Volatility Index reflects an unfavorable balance between upside participation and downside exposure.
Among Health Care peers, ImmunityBio occupies the same challenged tier as Zoetis Inc. (ZTS, D), BioNTech SE (BNTX, D-), and Natera, Inc. (NTRA, D-). With only a Fair Solvency Index offering partial balance-sheet support, the D (Sell) rating signals that caution is warranted until profitability and capital returns show meaningful and sustained improvement.
About ImmunityBio, Inc.
ImmunityBio, Inc. (IBRX) is a San Diego-based biotechnology company operating in the Health Care sector within Pharmaceuticals, Biotechnology and Life Sciences. The company is focused on developing and commercializing immunotherapies designed to harness a patient's immune system, with the goal of delivering more durable protection against cancer and infectious diseases. Like many clinical-stage biotech firms, ImmunityBio's profile is closely tied to a concentrated set of programs and platform technologies—a structure that makes its overall business highly dependent on regulatory milestones, manufacturing execution, and adoption within narrowly defined patient populations.
ImmunityBio's development toolkit spans cytokine fusion proteins, DNA and vaccine vectors, and cell therapies, with multiple candidates slated for evaluation across liquid and solid tumors in clinical trials. Its lead biologic product is Anktiva, an FDA-approved immunotherapy used in combination with bacillus calmette-guérin (BCG) for certain adult patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. Beyond Anktiva, the pipeline includes 3M-052, a synthetic TLR7/8 agonist along with related formulations and technology, reflecting a broader emphasis on immune activation approaches applicable across a range of disease targets.
The company also relies on external relationships to support the development of and access to key technologies, including collaborations with the National Cancer Institute, Serum Institute of India Private Limited, and BeOne Medicines Ltd., as well as licensing arrangements with 3M Innovative Properties Company and Access to Advanced Health Institute.
Investor Outlook
Carrying a Weiss Rating of D (Sell), ImmunityBio, Inc. (IBRX) presents an unfavorable risk/reward profile. Investors would be well served by exercising caution and waiting for concrete evidence of sustained improvement rather than reacting to short-term price fluctuations. Key markers to watch include whether the stock can defend recent support levels on diminishing selling pressure, how broader Health Care sentiment evolves around risk appetite, and whether the fundamental factors behind the D grade begin to stabilize in a meaningful way. Full rankings of all D-rated Health Care stocks are available inside the Weiss Stock Screener.
--